Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | LGMN | Q99538 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.41 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.41 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763203 | 0.81 | AGXT (0.48) | KMOAGXTLMNALGMNAR | |
| SCHEMBL23841128 | 0.81 | AGXT (0.50) | KMOAGXTLMNALGMNAR | |
| SCHEMBL4402783 | 0.77 | LMNA (0.53) | KMOAGXTLMNALGMNAR | |
| SCHEMBL14385886 | 0.77 | AGXT (0.44) | KMOAGXTLMNAPLOD2PLOD3 | |
| SCHEMBL20227232 | 0.75 | LMNA (0.50) | KMOAGXTLMNALGMNAR | |
| SCHEMBL5739149 | 0.74 | ALDH1A1 (0.66) | KMOLMNAARSLC6A9SLC6A5 | |
| SCHEMBL27329825 | 0.73 | LMNA (0.71) | KMOAGXTLMNALGMNAR | |
| SCHEMBL30087606 | 0.72 | KMO (0.54) | KMOAGXTLMNAPLOD2PLOD3 | |
| SCHEMBL17420638 | 0.72 | ALDH1A1 (0.53) | KMOLMNALGMNSLC6A9SLC6A5 | |
| SCHEMBL4507051 | 0.71 | AGXT (0.65) | KMOAGXTLMNALGMNPLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828349-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | EXONHIT THERAPEUTICS SA (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9399628-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9314466-B2 | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160083371-A1 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | EXONHIT THERAPEUTICS SA (FR) | 2016-03-24 | — | — | US | disclosed |
| US-9278943-B2 | Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | EXONHIT THERAPEUTICS SA (FR) | 2016-03-08 | — | — | US | disclosed |
| US-20160051555-A9 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-20150231140-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-20130310383-A1 | 1-ARYL -1-HYDROXY -2,3-DIAMINO-PROPYL AMIN ES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8513288-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120225881-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20110288094-A1 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8013000-B2 | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity | ALLERGAN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100190792-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC | 2010-07-29 | — | — | US | disclosed |
| EP-2198864-A1 | Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds | Allergan, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20100105687-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1841423-B1 | USE OF 1- BENZYL-1- HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO PROPIONIC ACID AMIDES AND RELATED COMPOUNDS AS ANALGESICS | ALLERGAN INC (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090088433-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-04-02 | — | — | US | disclosed |
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | EXONHIT THERAPEUTICS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| WO-2008109286-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008011487-A2 | L-BENZYL-L-HYDR0XY-2, 3-DIAMIN0-PROPYL AMINES AND 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONICACID AMIDES FOR CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312236-A1 | 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity | OPRL1, OPRM1, MRGPRX2 | KMO 567/4885AGXT 1598/4885LMNA 4800/4885 |
| US-20090088433-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | OPRL1, OPRK1, AADAT | KMO 175/4885AGXT 808/4885LMNA 2209/4885 |
| US-20130310383-A1 | 1-ARYL -1-HYDROXY -2,3-DIAMINO-PROPYL AMIN ES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRL1, OPRM1, OPRK1 | KMO 688/4885AGXT 2458/4885LMNA 4729/4885 |
| US-20160083371-A1 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRM1, OPRL1, MYD88 | KMO 422/4885AGXT 2107/4885LMNA 4826/4885 |
| US-20100105687-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | SLC1A2, PNMT, HTR2C | KMO 71/4885AGXT 210/4885LMNA 3390/4885 |
| US-20100190792-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, SLC1A1, GRIN2A | KMO 190/4885AGXT 117/4885LMNA 2290/4885 |
| US-20150231140-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2A, GRIN2C | KMO 187/4885AGXT 173/4885LMNA 2614/4885 |
| US-20160051555-A9 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2A, GRIN2C | KMO 187/4885AGXT 173/4885LMNA 2614/4885 |
| US-20110288094-A1 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRM1, OPRL1, MYD88 | KMO 422/4885AGXT 2107/4885LMNA 4826/4885 |
| US-20120225881-A1 | METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | OPRK1, OPRL1, HRH2 | KMO 221/4885AGXT 375/4885LMNA 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.